liraglutide (4P004) / 4P-Pharma - LARVOL DELTA

4Moving Biotech Secures €7.6M France 2030 Grant for Pioneering First-In-Class Disease-Modifying Osteoarthritis Drug (Businesswire) - "4Moving Biotech...announces that it has been awarded €7.6 million in funding under the France 2030 plan to accelerate the clinical development of its lead candidate, 4P004, currently in a Phase 2a trial....This additional funding will accelerate the 4P004 INFLAM MOTION Phase 2a clinical study, a GLP-1 analog designed to harness anti-inflammatory, analgesic, anti-catabolic, and anabolic effects across all joint tissues."

Financing • Osteoarthritis

Health Canada Authorizes 4Moving Biotech to Launch Phase 2a INFLAM MOTION Clinical Trial for Knee Osteoarthritis (Businesswire) - "4Moving Biotech...announces that it has been authorized by Health Canada to launch the Phase 2a INFLAM MOTION 'Proof-of-Concept' study for 4P004 in patients with knee osteoarthritis...The INFLAM MOTION Study is a Phase 2a multicenter, randomized, double-blind, placebo-controlled trial conducted in the EU, US, and Canada, including three sites in Canada. It will enroll 129 patients to evaluate, for the first time, the efficacy of 4P004 in individuals with knee osteoarthritis...4MB will proceed with the study initiation in Canada, including the first patient enrolment, which is expected in the second quarter of 2025."

New P2a trial • Inflammation • Osteoarthritis

The Anti-Inflammatory Effects of Liraglutide in Equine Inflammatory Joint Models. (PubMed, J Orthop Res) - "In conclusion, liraglutide demonstrates the potential to attenuate inflammatory processes in joint cells. Additional research is necessary to validate its efficacy within the complex milieu of an inflamed joint."

Journal • Immunology • Inflammation • Inflammatory Arthritis • Osteoarthritis • Pain • Rheumatology • CCL2 • IL1B

Beyond Pain and Inflammation: Intra-articular Liraglutide's Comprehensive Benefits on Synovial Health and Cartilage in Osteoarthritis Compared to Dexamethasone (ACR Convergence 2024) - "Here, we aimed to explore the analgesic, anti-inflammatory and protective effects of liraglutide (LIRA), a GLP-1 analogue, in an in vivo model of inflammatory OA in rats. The effects of one IA injection of LIRA, dexamethasone (DEX) or vehicle on analgesia and knee joint structure were evaluated in a monoiodoacetate (MIA) rat model. These results confirm that IA injection of LIRA effectively targets key aspects of OA, providing significant analgesic, anti-inflammatory, and joint structure protective effects. LIRA demonstrates greater potency compared to DEX in preserving synovial tissue and cartilage integrity. This underscores LIRA's potential as a superior treatment option for OA, addressing both symptomatic relief and structural preservation."

Immunology • Inflammation • Osteoarthritis • Pain • Rheumatology

4Moving Biotech announces successful results from its Lasare Phase I 4P004 Clinical Trial intraarticular Liraglutide for knee osteoarthritis patients (Businesswire) - P1 | N=34 | LASARE (NCT05419856) | Sponsor: 4Moving Biotech | "4Moving Biotech...announces the successful achievement of the Phase 1 Lasare trial in knee osteoarthritis (OA) patients using 4P004...The study evaluated the safety, tolerability, and pharmacokinetics of ascending doses of a single intra-articular injection of liraglutide (4P004). The trial reached its primary objective, confirming that intraarticular liraglutide (4P004) was safe and well tolerated. A pharmacological active dose has been identified, with similar expected adverse events (EAEs) in the 4P004 groups as the placebo group. Pharmacokinetics, both observed..."

P1 data • Osteoarthritis

Intra-articular Administration of Liraglutide Mitigates Synovial Tissue Alteration and Cartilage Degradation in Preclinical Osteoarthritis Models (OARSI 2024) - "Our team is focusing on glucagon-like peptide-1 (GLP-1) analogs, which have potential anti-inflammatory and tissue-protective effects beyond their antidiabetic properties. In this study, we aimed to explore the anti-inflammatory, anti-catabolic and anabolic effects of liraglutide, a GLP-1 analog, in two in vivo models of OA by evaluating structural changes and surrogate markers of catabolism and anabolism in synovial membrane and cartilage in rats."

Preclinical • Immunology • Osteoarthritis • Pain • Rheumatology

Anti-Inflammatory and Anabolic Effects of Liraglutide on 3D Inflammatory Osteoarthritic Pellets of Human Chondrocytes (OARSI 2024) - "Recent studies have shown that liraglutide exhibits anti-inflammatory, analgesic, anti-catabolic and cartilage regenerative properties in inflammatory and post-traumatic osteoarthritis (OA) animal models. This study aims to investigate the ability of liraglutide to reduce inflammation and increase anabolism in human chondrocytes in vitro ."

Diabetes • Immunology • Inflammation • Metabolic Disorders • Osteoarthritis • Pain • Rheumatology

LASARE: Safety, Tolerability and Pharmacokinetics of Intra-articular (IA) Single Ascending Dose of 4P-004 in Patient With Kellgren and Lawrence Grade 2 to 4 Osteoarthritic (OA) Knee (clinicaltrials.gov) - P1 | N=34 | Completed | Sponsor: 4Moving Biotech | Recruiting ➔ Completed | Trial completion date: Jan 2023 ➔ Oct 2023 | Trial primary completion date: Jan 2023 ➔ Oct 2023

Trial completion • Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology

4Moving Biotech Completes the Recruitment of Its Phase I Clinical Trial in Patients With Knee Osteoarthritis (Businesswire) - "4Moving Biotech...announces that it has reached a significant milestone by completing patient recruitment for its LASARE Phase I clinical trial....The Phase I clinical trial results are scheduled for Q1 2024."

Enrollment closed • P1 data • Osteoarthritis

Weight Loss: Gastric Balloon and Medications Led to 19% Drop in Weight - "'The most common side effect of each of these is nausea, but this improves with time and rarely requires stopping treatment,' says Mehal."

Media quote

Beneficial Structural Impact of Liraglutide, a GLP1 Receptor Agonist, in Three Inflammatory and Post-traumatic OA Animal Models (ACR Convergence 2022) - "Using 3 experimental models of OA, we have demonstrated a potential effect of liraglutide on the whole structure of the joint (cartilage, synovial tissue and bone) and not only on the cartilage, allowing us to consider this drug as a disease-modifier rather than a cartilage-modifier OA drug only.1 Meurot C et al. Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Sci Rep."

Preclinical • Diabetes • Immunology • Inflammation • Metabolic Disorders • Osteoarthritis • Pain • Rheumatology • Type 2 Diabetes Mellitus

LASARE: Safety, Tolerability and Pharmacokinetics of Intra-articular (IA) Single Ascending Dose of 4P-004 in Patient With Kellgren and Lawrence Grade 2 to 4 Osteoarthritic (OA) Knee (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: 4Moving Biotech | Trial completion date: Oct 2022 ➔ Jan 2023 | Trial primary completion date: Sep 2022 ➔ Jan 2023

Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology

10 Steps to Healing a Hypothyroid Liver - "When you have a hepatic hypothyroidism, thyroid tests are normal and adjusting thyroid medications or taking extra T3 does not work. The symptoms of a hypothyroid liver can be ignored, undiagnosed, and the root cause left untreated. A healthy liver is vital for optimal thyroid and whole-body function. Follow these 10 steps to manage hepatic hypothyroidism and heal a hypothyroid liver."

Online posting

LASARE: Safety, Tolerability and Pharmacokinetics of Intra-articular (IA) Single Ascending Dose of 4P-004 in Patient With Kellgren and Lawrence Grade 2 to 4 Osteoarthritic (OA) Knee (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: 4Moving Biotech | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Osteoarthritis • Pain • Rheumatology

LASARE: Safety, Tolerability and Pharmacokinetics of Intra-articular (IA) Single Ascending Dose of 4P-004 in Patient With Kellgren and Lawrence Grade 2 to 4 Osteoarthritic (OA) Knee (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: 4Moving Biotech

New P1 trial • Immunology • Osteoarthritis • Pain • Rheumatology